REG - Surgical Innovations - Directorate Change - Appointment of CFO

Surgical InnovationsAnnouncement

10/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240610:nRSJ6882Ra&default-theme=true

RNS Number : 6882R  Surgical Innovations Group PLC  10 June 2024

 

Surgical Innovations Group Plc

 ("Surgical Innovations", the "Company", or the "Group")

 

Directorate Change

Appointment of Chief Financial Officer

 Commercially focused MBA-qualified finance professional brings 20+ years of
relevant experience to the Group

 

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and
distributor of innovative technology for minimally invasive surgery, announces
the appointment of Chris Martin as Chief Financial Officer ("CFO") and an
Executive Director of the Board, effective Monday 10 June 2024. Chris takes
over from Interim Financial Consultant, Michael Roper, who will stay on to
provide a handover and facilitate a smooth transition.

 

Chris brings with him over 20 years' experience as a Finance Director in
various manufacturing organisations. His most recent role was with Weir Plc,
where he served as Regional Finance Director for Europe, North Africa, and
Central Asia for six years. Prior to this, from 2004, Chris held Finance
Director positions with Jeld-Wen UK, Laing O'Rourke, The Latium Group, and
Lafarge S.A.. He obtained an MBA in 2014 and began his finance career in
Lafarge Roofing Ltd (part of Lafarge S.A, formerly Redland Plc) in 1990.

 

CEO, David Marsh, commented: "Chris brings a wealth of experience in growing
and improving business performance, managing change, implementing new systems,
and developing high-performing teams. We are confident that his expertise and
leadership will be valuable to Surgical Innovations as we continue to drive
our strategic initiatives forward.

 

"We would also like to take this opportunity to thank Michael Roper, our
Interim Financial Consultant, for his guidance and advice over the past few
months."

 

The following details are disclosed pursuant to Schedule Two Paragraph (g) of
the AIM Rules for Companies:

 

Christopher ("Chris") Jonathan Martin, age 55, holds or has held the following
directorships in the past five years:

 

 Current Directorships
 None
 Directorships held within the last five years
 Weir Mineral Europe Limited

 

There are no further disclosures required to be made in relation to AIM Rule
17.

 

For further information please contact:

 

 Surgical Innovations Group plc                                                www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                                              Tel: 0113 230 7597

 Chris Martin, CFO

 Singer Capital Markets (Nominated Adviser & Broker)                                                     Tel: 020 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR (Financial PR & Investor Relations)      Tel: 020 7933 8780 or si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Charlotte Edgar                                                Mob: 07980 541 893 / 07884 664 686

 

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of
innovative, high quality medical products, primarily for use in minimally
invasive surgery. Our product and business development is guided and supported
by a key group of nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical
instruments and retraction devices which are sold directly in the UK home
market through our subsidiary, Elemental Healthcare, and exported widely
through a global network of trusted distribution partners. Many of our
products in this field are based on a "resposable" concept, in which the
products are part reusable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive against
fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select portfolio of
specialist products employed in laparoscopy, bariatric and metabolic surgery,
hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM
partners and have also collaborated with a major UK industrial partner to
provide precision engineering solutions to complex problems outside the
medical arena.

 

We aim for our brands to be recognised and respected by healthcare
professionals in all major geographical markets in which we operate and
provide by development, partnership or acquisition a broad portfolio of cost
effective, procedure specific surgical instruments and implantable devices
that offer reliable solutions to genuine clinical needs in the operating
theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the
following websites:

www.sigroupplc.com (http://www.sigroupplc.com)

www.surginno.com (http://www.surginno.com)

www.elementalhealthcare.co.uk (http://www.elementalhealthcare.co.uk)

 

To receive regular updates by email, please contact si@walbrookpr.com
(mailto:si@walbrookpr.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAKKXEEXLEFA